MPM Asset Management’s Werewolf Therapeutics HOWL Stock Holding History

MPM Asset Management’s Portfolio HOWL Stock Details HOWL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	$8.49M	Hold	4,309,860	–	–	19.08%	3
2025 Q2	$4.7M	Hold	4,309,860	–	–	10.84%	3
2025 Q1	$4.19M	Buy	4,309,860 +25,688	+0.6%	+$33.6K	6.03%	4
2024 Q4	$6.34M	Hold	4,284,172	–	–	5.1%	4
2024 Q3	$9.08M	Hold	4,284,172	–	–	6.25%	4
2024 Q2	$10.5M	Hold	4,284,172	–	–	5.74%	4
2024 Q1	$27.8M	Hold	4,284,172	–	–	11.32%	4
2023 Q4	$16.5M	Hold	4,284,172	–	–	8.13%	4
2023 Q3	$9.17M	Hold	4,284,172	–	–	4.91%	5
2023 Q2	$13.1M	Hold	4,284,172	–	–	6.41%	5
2023 Q1	$11.1M	Hold	4,284,172	–	–	4.64%	6
2022 Q4	$8.78M	Hold	4,284,172	–	–	3.67%	6
2022 Q3	$19.3M	Hold	4,284,172	–	–	7.36%	5
2022 Q2	$17.5M	Hold	4,284,172	–	–	7.39%	6
2022 Q1	$18.9M	Hold	4,284,172	–	–	6.44%	6
2021 Q4	$51M	Hold	4,284,172	–	–	11.03%	4
2021 Q3	$73.5M	Hold	4,284,172	–	–	17.04%	3
2021 Q2	$74.7M	Buy	+4,284,172	New	+$58.7M	13.89%	3

Other funds holding HOWL

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return

DC Funds Mclean, Virginia $1.25M AUM 26.51% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

MPM Asset Management's HOWL Position: Q3 2025 in Review

MPM Asset Management held its Werewolf Therapeutics (HOWL) position steady in Q3 2025 at 4,309,860 shares worth $8.49M. The position accounts for 19.08% of the portfolio, ranked #3.

MPM Asset Management first reported a position in HOWL in Q2 2021 and has held it in 18 quarters since. The position peaked at $74.7M in Q2 2021. 62 funds tracked by Wall St. Rank hold HOWL as of Q3 2025.

MPM Asset Management held 4,309,860 shares of Werewolf Therapeutics worth $8.49M as of Q3 2025.
MPM Asset Management left its Werewolf Therapeutics share count unchanged in Q3 2025.
Werewolf Therapeutics made up 19.08% of MPM Asset Management's portfolio in Q3 2025, its #3 holding.
MPM Asset Management first reported a position in Werewolf Therapeutics in Q2 2021 and has held it in 18 quarters since.
MPM Asset Management's Werewolf Therapeutics position peaked at $74.7M in Q2 2021.
62 funds tracked by Wall St. Rank held Werewolf Therapeutics as of Q3 2025.

Based on MPM Asset Management's 13F filing for Q3 2025, filed 14 Nov 2025.